Career Enhancement Program (CEP)
职业提升计划(CEP)
基本信息
- 批准号:10684244
- 负责人:
- 金额:$ 13.1万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-08-03 至 2025-07-31
- 项目状态:未结题
- 来源:
- 关键词:AchievementAmerican Association of Cancer ResearchAttentionCancer CenterCareer MobilityClinicalCollaborationsConsultationsDana-Farber Cancer InstituteDedicationsDiagnosisEducational process of instructingEnvironmentExtramural ActivitiesFacultyFosteringFundingGenderGoalsGrantGynecologic OncologyHospitalsIndividualInstitutionInternationalIsraelLeadershipMalignant neoplasm of ovaryMeasuresMedical centerMentorsMinority RecruitmentMonitorNew EnglandOncologyOutcomeOutcome MeasurePaperPatientsPeer ReviewPersonsPopulationProcessPublic HealthPublicationsPublished CommentResearch PersonnelResourcesSecureSocietiesSourceSupervisionTalentsTrainingTraining ProgramsTranslatingTranslational ResearchWorkanticancer researchcancer therapycandidate selectioncareercareer developmentdrug developmentethnic diversityfaculty supportgender diversityinstructormedical schoolsmembernovel therapeuticsprofessorprogramsrapid growthrecruitsenior facultysuccesstranslational cancer researchtranslational impacttranslational scientist
项目摘要
Project Summary
CAREER ENHANCEMENT PROGRAM
THE OVERALL OBJECTIVE of the Career Advancement Program will be: to increase the breadth and depth of
the ovarian cancer translational investigator pool at the DF/HCC and across the US. We expect to train
individuals who will become 2025’s National / International leaders in the pathobiology, diagnosis, treatment
and control of Ovarian Cancers. The program will be led by Dr. David Spriggs, one of the overall SPORE PI’s
and with the ongoing advice and consultation of Drs D’Andrea and Dr. Steve Cannistra. Dr. Spriggs has a long
track record of successful recruiting and mentoring new academic investigators into new drug development
and ovarian cancer treatment. The Specific aims will define the Career Enhancement Program: Aim 1.
Identify appropriate candidates, primarily junior faculty members seeking to become independent investigators
in ovarian cancer research, provide and secure funding for these investigators, and assure SPORE resources
for awardees. This group will include applicants from the rich DFHCC pool of fellows and junior faculty as well
as candidates from the other New England Institutions, Collaborating SPORE’s and national candidates
solicited from AACR and the Society of Gynecologic Oncology. We are particularly committed to increase the
diversity of the peer reviewed translational science investigators in ovarian cancer. Selection will rely on the
entire SPORE leadership and be confirmed by the EAB. Aim 2. Promote a mentoring environment and plan
that will assist the career enhancement and success of the CEP awardees. Through the environment in the
DF/HCC, we will create individualized training programs (IDP’s)for every funded junior faculty person and build
a team of scientific, clinical and personal mentors around each one; Aim 3. Monitor the scientific and
academic progress of the awardees and the program. Particular attention will be given transition points, such
as the instructor/assistant professor interface and the attainment of RO1 equivalent funding which will mark
transition to full independence. Short term outcome measures will include publication of high impact papers
and the submission of extramural peer reviewed funding. Long term outcomes will be persistence in ovarian
cancer translational research as measured by continuing peer reviewed publication in ovarian cancer research
and achievement of senior faculty status at academic institutions 5-7 years after completion of the CEP
completion. The majority of support will come from a variety of institutional sources from the DFHCC, the
DFCI, the Beth Israel Deaconess Medical Center and the MGH. Specific plans for the identification, recruitment
and mentoring of a diverse awardee pool will incorporate resources for specific gender and minority
recruitment efforts from Harvard Medical School and the individual hospitals involved in the SPORE.
项目摘要
职业提升计划
职业发展计划的总体目标是:增加以下方面的广度和深度:
DF/HCC和美国各地的卵巢癌转化研究者库。我们希望训练
这些人将成为2025年病理学、诊断、治疗和康复领域的国家/国际领导者。
控制卵巢癌。该计划将由大卫斯普里格斯博士领导,他是整个孢子PI的一员
以及D 'Andrea博士和Steve Cannistra博士的持续建议和咨询。斯普里格斯博士有一个很长的
成功招募和指导新的学术研究人员进入新药开发的跟踪记录
和卵巢癌治疗。具体目标将界定职业提升计划:目标1。
确定合适的候选人,主要是寻求成为独立调查员的初级教员
在卵巢癌研究中,为这些研究人员提供并确保资金,并确保SPORE资源
获奖者。这个小组将包括申请人从丰富的DFHCC池的研究员和初级教师以及
作为其他新英格兰机构的候选人,合作孢子和国家候选人
从AACR和妇科肿瘤学会征集。我们特别致力于增加
卵巢癌的同行评审转化科学研究者的多样性。选择将取决于
整个SPORE领导层,并由EAB确认。目标二。促进辅导环境和计划
这将有助于职业发展和CEP获奖者的成功。通过环境中的
DF/HCC,我们将为每个资助的初级教师创建个性化的培训计划(IDP),并建立
一个由科学、临床和个人导师组成的团队;目标3。监测科学和
获奖者和项目的学术进展。将特别注意过渡点,例如
作为讲师/助理教授接口和达到RO 1同等资金,这将标志着
过渡到完全独立。短期成果措施将包括发表影响力大的论文
以及提交校外同行评审资金。长期结果将是卵巢癌的持续性
卵巢癌研究中持续同行评审出版物衡量的癌症转化研究
并在完成CEP 5-7年后在学术机构获得高级教师地位
建成大部分的支持将来自DFHCC,
DFCI,贝斯以色列女执事医疗中心和MGH。具体计划为确定、招聘
多样化的获奖者库将纳入特定性别和少数群体的资源
来自哈佛医学院和参与SPORE的各个医院的招聘工作。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Cesar M Castro其他文献
Cesar M Castro的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Cesar M Castro', 18)}}的其他基金
Expanding early cancer detection with high throughput OCEANA - Ovarian Cancer Exosome Analysis with Nanoplasmonic Array
利用高通量 OCEANA 扩大早期癌症检测 - 使用纳米等离子体阵列进行卵巢癌外泌体分析
- 批准号:
10762488 - 财政年份:2023
- 资助金额:
$ 13.1万 - 项目类别:
Composing CODAs to cervical cancer screening through an integrated CRISPR and fluorescent nucleic acid approach
通过集成 CRISPR 和荧光核酸方法将 CODA 应用于宫颈癌筛查
- 批准号:
10647930 - 财政年份:2023
- 资助金额:
$ 13.1万 - 项目类别:
High throughput nanoplasmonic exosome testing (NEXT) of immunotherapies in bladder cancer
膀胱癌免疫疗法的高通量纳米等离子体外泌体测试(NEXT)
- 批准号:
10463778 - 财政年份:2021
- 资助金额:
$ 13.1万 - 项目类别:
High throughput nanoplasmonic exosome testing (NEXT) of immunotherapies in bladder cancer
膀胱癌免疫疗法的高通量纳米等离子体外泌体测试(NEXT)
- 批准号:
10686016 - 财政年份:2021
- 资助金额:
$ 13.1万 - 项目类别:
High throughput nanoplasmonic exosome testing (NEXT) of immunotherapies in bladder cancer
膀胱癌免疫疗法的高通量纳米等离子体外泌体测试(NEXT)
- 批准号:
10305371 - 财政年份:2021
- 资助金额:
$ 13.1万 - 项目类别:
Dana Farber/Harvard Cancer Center Ovarian Cancer SPORE grant
达纳法伯/哈佛大学癌症中心卵巢癌孢子补助金
- 批准号:
10684196 - 财政年份:2020
- 资助金额:
$ 13.1万 - 项目类别:
Dana Farber/Harvard Cancer Center Ovarian Cancer SPORE grant
达纳法伯/哈佛大学癌症中心卵巢癌孢子补助金
- 批准号:
10469368 - 财政年份:2020
- 资助金额:
$ 13.1万 - 项目类别:
Early Detection through Novel OCEAN Technology - Ovarian Cancer Exosomal Analysis with Nanoplasmonics
通过新型 OCEAN 技术进行早期检测 - 使用纳米等离子体技术进行卵巢癌外泌体分析
- 批准号:
9982238 - 财政年份:2018
- 资助金额:
$ 13.1万 - 项目类别:
Early Detection through Novel OCEAN Technology - Ovarian Cancer Exosomal Analysis with Nanoplasmonics
通过新型 OCEAN 技术进行早期检测 - 使用纳米等离子体技术进行卵巢癌外泌体分析
- 批准号:
10223236 - 财政年份:2018
- 资助金额:
$ 13.1万 - 项目类别: